rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

enGene Therapeutics Inc.

ENGN · Nasdaq

Health CareBiotechnologyNot moving yet

ENGN stood above a rising 150-day average in 20 of the last 52 weekly readings, and has been out of that trend for the last 32 weeks. It is 47.4% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 32
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$20K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
57 (-2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 20 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$19KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months1
Sale orders, 12 months0
Buyers · sellers1 · 0
WhoDidSharesTraded
William GrossmanInterim Chief Medical Officerbought5,102at $1.9722 Sep 2026filed 24 Sep 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders57-2 on the quarter
New · exited19 · 21
Reported value$86.4M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
FCPM III SERVICES B.V.unchanged · filed 14 Aug 20269,632,561$16.7M00.0%
BML Capital Management, LLCnew · filed 7 Aug 20266,669,908$11.5M+6,669,908
Siren, L.L.C.added · filed 13 Aug 20266,256,662$10.8M+1,003,503+19.1%
PERCEPTIVE ADVISORS LLCreduced · filed 14 Aug 20264,822,169$8.3M-1,005,337−17.3%
AMERIPRISE FINANCIAL INCnew · filed 14 Aug 20262,675,876$4.6M+2,675,876
Nextech Invest Ltd.unchanged · filed 14 Aug 20262,324,943$4.0M00.0%
ADAR1 Capital Management, LLCadded · filed 14 Aug 20262,104,986$3.6M+1,971,300+1474.6%
Vestal Point Capital, LPreduced · filed 14 Aug 20261,667,430$2.9M-497,570−23.0%
ACORN CAPITAL ADVISORS, LLCnew · filed 14 Aug 20261,271,257$2.2M+1,271,257
Peapod Lane Capital LLCnew · filed 27 Jul 20261,102,149$1.9M+1,102,149
31 Dec 2023 – 30 Jun 2026
133557Dec 23Sep 24Mar 25Dec 25Jun 26

Everyone who traded it

William Grossman Company insiderInterim Chief Medical Officer · last 22 Sep 20261 · 0
Gerald A. Brunk Company insiderDirector · last 16 Jun 20260 · 0
Lota S. Zoth Company insiderDirector · last 16 Jun 20260 · 0
Michael Thomas Heffernan Company insiderDirector · last 16 Jun 20260 · 0
Paul J. Hastings Company insiderDirector · last 16 Jun 20260 · 0
Philip Astley-Sparke Company insiderDirector · last 16 Jun 20260 · 0
Richard M. Glickman Company insiderDirector · last 16 Jun 20260 · 0
Wouter Joustra Company insiderDirector · last 16 Jun 20260 · 0
Alexander Julian Nichols Company insiderChief Strategy & Ops. Ofc · last 30 Jan 20260 · 0
Anthony Tzeyew Cheung Company insiderChief Scientific Officer · last 30 Jan 20260 · 0
D. Ryan Daws Company insiderChief Financial Officer · last 30 Jan 20260 · 0
Jill Buck Company insiderChief Development Officer · last 30 Jan 20260 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Oct 2025-65.0%
Share count trendFY 2025 · to 18 Dec 202528.8%
Cash and equivalentsFY 2025 · to 31 Oct 2025$50.2M
Free cash flowFY 2025 · to 31 Oct 2025−$100.7M

Analyst forecasts

No analyst forecasts yet.